Meag Munich Ergo Kapitalanlagegesellschaft MBH lowered its stake in The Cooper Companies, Inc. (NYSE:COO) by 88.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,708 shares of the medical device company’s stock after selling 28,315 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in The Cooper Companies were worth $831,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in COO. Atria Investments LLC increased its holdings in shares of The Cooper Companies by 14.2% in the fourth quarter. Atria Investments LLC now owns 2,233 shares of the medical device company’s stock valued at $487,000 after purchasing an additional 277 shares during the period. Bank of Montreal Can grew its holdings in The Cooper Companies by 26.7% during the fourth quarter. Bank of Montreal Can now owns 107,677 shares of the medical device company’s stock worth $23,460,000 after acquiring an additional 22,722 shares during the period. National Pension Service grew its holdings in The Cooper Companies by 19,420.5% during the fourth quarter. National Pension Service now owns 57,000 shares of the medical device company’s stock worth $12,419,000 after acquiring an additional 56,708 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in The Cooper Companies by 1.9% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 195,133 shares of the medical device company’s stock worth $42,516,000 after acquiring an additional 3,583 shares during the period. Finally, CAPROCK Group Inc. acquired a new position in The Cooper Companies during the fourth quarter worth $222,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.
COO opened at $225.57 on Tuesday. The company has a current ratio of 2.83, a quick ratio of 1.61 and a debt-to-equity ratio of 0.75. The firm has a market cap of $11.11 billion, a price-to-earnings ratio of 23.25, a PEG ratio of 1.78 and a beta of 0.62. The Cooper Companies, Inc. has a one year low of $204.51 and a one year high of $260.26.
The Cooper Companies (NYSE:COO) last posted its earnings results on Thursday, March 8th. The medical device company reported $2.79 EPS for the quarter, topping the Zacks’ consensus estimate of $2.51 by $0.28. The company had revenue of $590.00 million for the quarter, compared to the consensus estimate of $583.07 million. The Cooper Companies had a return on equity of 16.90% and a net margin of 7.83%. The Cooper Companies’s quarterly revenue was up 18.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.93 earnings per share. equities analysts anticipate that The Cooper Companies, Inc. will post 11.82 earnings per share for the current year.
A number of research analysts recently weighed in on the company. Cleveland Research lowered The Cooper Companies from a “buy” rating to a “hold” rating in a report on Friday, February 9th. TheStreet lowered The Cooper Companies from a “b” rating to a “c” rating in a report on Thursday, March 8th. BMO Capital Markets reaffirmed an “outperform” rating and set a $280.00 price objective (up previously from $277.00) on shares of The Cooper Companies in a report on Friday, March 9th. Goldman Sachs assumed coverage on The Cooper Companies in a report on Wednesday, April 4th. They set a “neutral” rating and a $231.00 price objective on the stock. Finally, Oppenheimer set a $265.00 price objective on The Cooper Companies and gave the stock a “hold” rating in a report on Friday, March 9th. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $264.18.
In other The Cooper Companies news, Director Michael Kalkstein sold 1,715 shares of the business’s stock in a transaction on Wednesday, April 11th. The stock was sold at an average price of $221.66, for a total transaction of $380,146.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Carol R. Kaufman sold 13,362 shares of the business’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $243.88, for a total value of $3,258,724.56. Following the sale, the executive vice president now owns 59,305 shares in the company, valued at $14,463,303.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,846 shares of company stock worth $12,549,839. 1.60% of the stock is owned by company insiders.
About The Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NYSE:COO).
Receive News & Ratings for The Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.